Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.

NCT07893561 · tracked via the Priya Life Science USA tracker
Sponsor
Bioligent
Phase
Not applicable
Started
2026-09-09
Last updated
2026-10-26

Condition(s) studied

Improves Daytime Energy LevelsReduces Afternoon Energy Crashes and Midday FatigueImproves Overall Sleep Quality and Restorative SleepHelps People Fall Asleep Faster and Wake Less During the NightHelps People Wake Feeling RefreshedImproves the Body's Resilience and Recovery in Response to Everyday StressReduces Perceived Stress and Feelings of OverwhelmImproves Cognitive Performance, Mental Clarity, and Calm Focus Throughout the DayProvides Calm, Steady Energy Without Jitteriness or OverstimulationReduces Reliance on Caffeine for Daily Energy

Investigational drug(s) / intervention(s)

Adrenal Adapt

Adrenal Adapt: All enrolled participants take 1 capsule of Adrenal Adapt three times daily (once in the morning with the first meal of the day, once in the afternoon with the midday meal, and once in the evening with the evening meal), not to exceed 3 capsules per day, for 12 weeks.

Study summary

This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive performance over a 12-week intervention period in 40 healthy adults aged 18-60.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion criteria: * Adults aged 18-60 years at the time of enrollment. * Experiencing difficulty with at least two of the following: sleep quality (including difficulty falling asleep, nighttime awakenings, or unrefreshing sleep), daytime fatigue or low energy, and/or subjective feelings of elevated stress. * Generally healthy - does not live with any uncontrolled chronic disease that would interfere with study participation or confound study outcomes. * If currently taking medications, supplements, or herbal remedies targeting sleep, stress, or energy, willing to maintain that routine unchanged for the study duration without introducing any other new products. * Willing to take 1 capsule of Adrenal Adapt three times daily with a meal (morning, afternoon, evening) for 12 weeks, not exceeding 3 capsules per day. * Willing to avoid excessive caffeine and alcohol for the duration of the study, defined as more than 400mg of caffeine per day, more than 15 alcoholic drinks per week for men and more than 7 alcoholic drinks per week for women. * Willing to maintain their current diet, sleep habits, and activity levels for the duration of the trial. * Resides in the United States with a valid shipping address. * Has consistent access to a smartphone or computer and a reliable internet connection sufficient to complete digital surveys. Exclusion criteria: * Currently pregnant, breastfeeding, or planning to become pregnant at any point during the study period. * Currently taking anticoagulant medications (e.g., warfarin, heparin, or direct oral anticoagulants), as specified in the product's known contraindications. * Known allergy or hypersensitivity to any ingredient in Adrenal Adapt (including Hypromellose capsule shell, white rice flour, stearic acid, silicon dioxide, or any of the botanical extracts). * Diagnosed with a clinically significant psychiatric disorder (e.g., major depressive disorder or bipolar disorder) that could confound subjective outcome assessments or interfere with study participation. * Diagnosed with a sleep disorder for which pharmacological treatment has been prescribed (e.g., narcolepsy, sleep apnea treated with a CPAP device and prescription medications, insomnia disorder treated with prescription hypnotics). * Generated by Citruslabs · 02c23d89-a524-4659-bc54-5792f4592244 Planning to introduce any new prescription medications, supplements, or herbal products targeting sleep, stress, or energy during the study period. * History of substance use disorder or currently using recreational drugs that may affect sleep or stress physiology. * Planning surgery or a major medical procedure during the 12- week study period. * Currently enrolled in or planning to enroll in another research study during the study period.

Primary outcome measure(s)

  • Change in Overall Sleep Quality — Baseline to Week 12
    Change from Baseline in self-reported overall sleep quality (restorative sleep), as assessed by validated sleep quality questionnaire items
  • Change in Sleep Onset Latency — Baseline to Week 12
    Change from Baseline in self-reported speed of falling asleep, as assessed by validated sleep quality questionnaire items
  • Change in Nighttime Awakenings — Baseline to Week 12
    Change from Baseline in self-reported frequency of nighttime awakenings (sleep maintenance), as assessed by validated sleep quality questionnaire items
  • Change in Subjective Morning Refreshment — Baseline to Week 12
    Change from Baseline in self-reported subjective sense of waking refreshed, as assessed by validated sleep quality questionnaire items

Trial sites (1)

FacilityCityRegionStatus
Citruslabs Las Vegas Nevada Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07893561 on ClinicalTrials.gov ↗ ← All trials in the USA